Ingmar Wahlqvist
Directeur/Membre du Conseil chez Cardiora Pty Ltd.
Profil
Ingmar Wahlqvist currently works at Protego Medical Pty Ltd., as Director, Cardiora Pty Ltd., as Director, Denteric Pty Ltd., as Director, George Medicines UK Ltd., as Director, and Brandon Capital Partners Pty Ltd., as Senior Investment Manager from 2009.
Postes actifs de Ingmar Wahlqvist
| Sociétés | Poste | Début |
|---|---|---|
Brandon Capital Partners Pty Ltd.
 Brandon Capital Partners Pty Ltd. Investment ManagersFinance Brandon Capital Partners Pty Ltd. (Brandon Capital Partners) is a venture capital firm founded in 2007 by David Fisher and Chris Nave. The firm is headquartered in Sydney, Australia. | Private Equity Investor | 01/08/2009 |
Protego Medical Pty Ltd.
 Protego Medical Pty Ltd. Medical SpecialtiesHealth Technology Protego Medical Pty Ltd. operates as an early stage medical technology company developing a medical device for sternal protection during cardiac surgery. The firm offers Sternal Haemostasis and protection during cardiac surgery, and Sternal Protection Device (SPD). The company was founded in 2013 and is headquartered in Melbourne, Australia. | Directeur/Membre du Conseil | - |
Cardiora Pty Ltd.
 Cardiora Pty Ltd. Investment Trusts/Mutual FundsMiscellaneous Cardiora Pty Ltd. functions as a clinical stage pharmaceutical company. It develops CRD-102, an oral medicine for heart failure. The company was founded by David Kaye in 2015 and is headquartered in Melbourne, Australia. | Directeur/Membre du Conseil | - |
Denteric Pty Ltd.
 Denteric Pty Ltd. Miscellaneous Commercial ServicesCommercial Services Denteric Pty Ltd. is a biotechnology company focused on oral health. It provides developing vaccines for treating and preventing severe periodontal disease. The company was founded by Eric C. Reynolds and is headquartered in Melbourne, Australia. | Directeur/Membre du Conseil | - |
George Medicines UK Ltd.
 George Medicines UK Ltd. BiotechnologyHealth Technology George Medicines UK Ltd. is a company focused on late stage drug development to improve the management of non-communicable diseases. The company is based in London, UK. The British company does this by creating single-pill, multi-mechanism combinations of existing medicines. Stefan König has been the CEO of the company since 2021. | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Brandon Capital Partners Pty Ltd.
Brandon Capital Partners Pty Ltd. Investment ManagersFinance Brandon Capital Partners Pty Ltd. (Brandon Capital Partners) is a venture capital firm founded in 2007 by David Fisher and Chris Nave. The firm is headquartered in Sydney, Australia. | Finance |
Protego Medical Pty Ltd.
Protego Medical Pty Ltd. Medical SpecialtiesHealth Technology Protego Medical Pty Ltd. operates as an early stage medical technology company developing a medical device for sternal protection during cardiac surgery. The firm offers Sternal Haemostasis and protection during cardiac surgery, and Sternal Protection Device (SPD). The company was founded in 2013 and is headquartered in Melbourne, Australia. | Health Technology |
Cardiora Pty Ltd.
Cardiora Pty Ltd. Investment Trusts/Mutual FundsMiscellaneous Cardiora Pty Ltd. functions as a clinical stage pharmaceutical company. It develops CRD-102, an oral medicine for heart failure. The company was founded by David Kaye in 2015 and is headquartered in Melbourne, Australia. | Miscellaneous |
Denteric Pty Ltd.
Denteric Pty Ltd. Miscellaneous Commercial ServicesCommercial Services Denteric Pty Ltd. is a biotechnology company focused on oral health. It provides developing vaccines for treating and preventing severe periodontal disease. The company was founded by Eric C. Reynolds and is headquartered in Melbourne, Australia. | Commercial Services |
George Medicines UK Ltd.
George Medicines UK Ltd. BiotechnologyHealth Technology George Medicines UK Ltd. is a company focused on late stage drug development to improve the management of non-communicable diseases. The company is based in London, UK. The British company does this by creating single-pill, multi-mechanism combinations of existing medicines. Stefan König has been the CEO of the company since 2021. | Health Technology |
